Menger, Björn

[["dc.bibliographiccitation.artnumber","6893137"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Journal of Nutrition and Metabolism"],["dc.bibliographiccitation.lastpage","9"],["dc.bibliographiccitation.volume","2016"],["dc.contributor.author","Hoffmann, Daniel B."],["dc.contributor.author","Griesel, Markus H."],["dc.contributor.author","Brockhusen, Bastian"],["dc.contributor.author","Tezval, Mohammad"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Menger, Bjoern"],["dc.contributor.author","Wassmann, Marco"],["dc.contributor.author","Stuermer, Klaus Michael"],["dc.contributor.author","Sehmisch, Stephan"],["dc.date.accessioned","2019-07-09T11:42:06Z"],["dc.date.available","2019-07-09T11:42:06Z"],["dc.date.issued","2016"],["dc.description.abstract","Background. 8-Prenylnaringenin (8-PN) is the phytoestrogen with the highest affinity for estrogen receptor-𝛼� (ER-𝛼�), which is required to maintain BMD. The osteoprotective properties of 8-PN have been demonstrated previously in tibiae. We used a rat osteopenia model to perform the first investigation of 8-PN with whole-body vertical vibration (WBVV). Study Design. Ovariectomy was performed on 52 of 64 Sprague-Dawley rats. Five weeks after ovariectomy, one group received daily injections (sc) of 8-PN (1.77mg/kg) for 10 weeks; a second group was treated with both 8-PN and WBVV (twice a day, 15 min, 35Hz, amplitude 0.47 mm). Other groups received either onlyWBVV or no treatment. Methods.The rats were sacrificed 15 weeks after ovariectomy. Lumbar vertebrae and femora were removed for biomechanical and morphological assessment. Results. 8-PN at a cancer-safe dose did not cause fundamental improvements in osteoporotic bones. Treatmentwith 8-PN caused a slight increase in uterine wetweight. Combined therapy using WBVV and 8-PN showed no significant improvements in bone structure and biomechanical properties. Conclusion. We cannot confirm the osteoprotective effects of 8-PN at a cancer-safe dose in primary affected osteoporotic bones. Higher concentrations of 8-PN are not advisable for safety reasons. Adjunctive therapy with WBVV demonstrates no convincing effects on bones."],["dc.identifier.doi","10.1155/2016/6893137"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12873"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58593"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-0732"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Effects of 8-Prenylnaringenin and Whole-Body Vibration Therapy on a Rat Model of Osteopenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","4"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Nutrition & Metabolism"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Saul, Dominik"],["dc.contributor.author","Weber, Marie"],["dc.contributor.author","Zimmermann, Marc Hendrik"],["dc.contributor.author","Kosinsky, Robyn Laura"],["dc.contributor.author","Hoffmann, Daniel Bernd"],["dc.contributor.author","Menger, Björn"],["dc.contributor.author","Taudien, Stefan"],["dc.contributor.author","Lehmann, Wolfgang"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Sehmisch, Stephan"],["dc.date.accessioned","2019-07-09T11:49:50Z"],["dc.date.accessioned","2020-06-09T07:03:29Z"],["dc.date.available","2019-07-09T11:49:50Z"],["dc.date.available","2020-06-09T07:03:29Z"],["dc.date.issued","2019"],["dc.description.abstract","Background Osteoporosis is one of the world’s major medical burdens in the twenty-first century. Pharmaceutical intervention currently focusses on decelerating bone loss, but phytochemicals such as baicalein, which is a lipoxygenase inhibitor, may rescue bone loss. Studies evaluating the effect of baicalein in vivo are rare. Methods We administered baicalein to sixty-one three-month-old female Sprague-Dawley rats. They were divided into five groups, four of which were ovariectomized (OVX) and one non-ovariectomized (NON-OVX). Eight weeks after ovariectomy, bilateral tibial osteotomy with plate osteosynthesis was performed and bone formation quantified. Baicalein was administered subcutaneously using three doses (C1: 1 mg/kg BW; C2: 10 mg/kg BW; and C3: 100 mg/kg BW) eight weeks after ovariectomy for four weeks. Finally, femora and tibiae were collected. Biomechanical tests, micro-CT, ashing, histological and gene expression analyses were performed. Results Biomechanical properties were unchanged in tibiae and reduced in femora. In tibiae, C1 treatment enhanced callus density and cortical width and decreased callus area. In the C3 group, callus formation was reduced during the first 3 weeks after osteotomy, correlating to a higher mRNA expression of Osteocalcin, Tartrate-resistant acid phosphatase and Rankl. In femora, baicalein treatments did not alter bone parameters. Conclusions Baicalein enhanced callus density and cortical width but impaired early callus formation in tibiae. In femora, it diminished the biomechanical properties and calcium-to-phosphate ratio. Thus, it is not advisable to apply baicalein to treat early bone fractures. To determine the exact effects on bone healing, further studies in which baicalein treatments are started at different stages of healing are needed."],["dc.identifier.doi","10.1186/s12986-018-0327-2"],["dc.identifier.pmid","30651746"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15789"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59640"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66212"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1743-7075"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Effect of the Lipoxygenase Inhibitor Baicalein on Bone Tissue and Bone Healing in Ovariectomized Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","118"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","European Journal of Applied Physiology"],["dc.bibliographiccitation.lastpage","130"],["dc.bibliographiccitation.volume","124"],["dc.contributor.author","Saul, D."],["dc.contributor.author","Ninkovic, M."],["dc.contributor.author","Komrakova, M."],["dc.contributor.author","Wolff, P."],["dc.contributor.author","Simka, P."],["dc.contributor.author","Gasimov, T."],["dc.contributor.author","Menger, B."],["dc.contributor.author","Hoffmann, D. B."],["dc.contributor.author","Rohde, V."],["dc.contributor.author","Sehmisch, S."],["dc.date.accessioned","2020-06-15T06:51:43Z"],["dc.date.available","2020-06-15T06:51:43Z"],["dc.date.issued","2017"],["dc.description.abstract","Estrogen deficiency and aging are associated with osteoporosis, impaired bone healing, and lower cognitive performance. Close functional and physical connections occur between bone and the central nervous system. An anti-inflammatory drug, zileuton (which is an inhibitor of arachidonate 5-lipoxygenase), is known to have a positive effect on bone tissue repair and brain ischemia. We studied the effect of zileuton on osteopenic bone and its healing and on the genes considered to be crucial for the cross talks between bone and brain. Three-month-old Sprague-Dawley rats were ovariectomized or left untreated. After 8 wk, bilateral metaphyseal tibia osteotomy with plate osteosynthesis was performed in all rats. Ovariectomized rats were fed with food containing zileuton (1, 10, or 100 mg/kg body wt) for 5 wk. In tibiae, bone volume, callus and cortical volume, and gene expression of osteocalcin and alkaline phosphatase were enhanced by zileuton (10 or 100 mg); biomechanical properties and bone density were not changed. In femur, zileuton enlarged cortical volume distal and trabecular volume proximal, decreasing their density. The expression level of brain Sema3a, known to regulate bone mass positively, was downregulated after ovariectomy. In contrast, bone Sema4d, a negative regulator of bone mass, was upregulated in the tibia callus after ovariectomy, whereas zileuton treatment (10 or 100 mg) resulted in reverse effects. Here, we describe for the first time the expression of Rbbp4 mRNA and its increase in tibia after ovariectomy. Zileuton caused downregulation of Rbbp4 in the hippocampus and had an effect on bone healing, changed the expression of genes involved in cross talk between bones and brain, and may be a potent drug for further examination in estrogen deficiency-related dysfunction(s)."],["dc.identifier.doi","10.1152/japplphysiol.01126.2016"],["dc.identifier.pmid","28860177"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66241"],["dc.language.iso","en"],["dc.relation.eissn","1522-1601"],["dc.relation.issn","8750-7587"],["dc.title","Effect of zileuton on osteoporotic bone and its healing, expression of bone and brain genes in rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Journal of Nutrition and Metabolism"],["dc.bibliographiccitation.lastpage","14"],["dc.bibliographiccitation.volume","2016"],["dc.contributor.author","Saul, D."],["dc.contributor.author","Kling, J. H."],["dc.contributor.author","Kosinsky, R. L."],["dc.contributor.author","Hoffmann, D. B."],["dc.contributor.author","Komrakova, M."],["dc.contributor.author","Wick, M."],["dc.contributor.author","Menger, B."],["dc.contributor.author","Sehmisch, S."],["dc.date.accessioned","2019-07-09T11:43:04Z"],["dc.date.accessioned","2020-06-15T07:13:16Z"],["dc.date.available","2019-07-09T11:43:04Z"],["dc.date.available","2020-06-15T07:13:16Z"],["dc.date.issued","2016"],["dc.description.abstract","Sarcopenia, a loss of muscle mass accompanying osteoporosis, leads to falls and fall-related injuries. Baicalein, as a phytochemical agent, has an antioxidative and anti-inflammatory effect inmuscle. In this study, sixty-one female SpragueDawley rats were divided into five groups: four groups were ovariectomized (OVX) and one control group was nonovariectomized (NON-OVX). Eight weeks after ovariectomy, three disparate concentrations (1mg/kg body weight (BW), 10mg/kg BW, and 100mg/kg BW) of baicalein were applied subcutaneously daily in three OVX groups. Mm. soleus, gastrocnemius, and longissimus were extracted; their diameter, area, relation to body, andmuscleweights aswell as number of capillaries per fibrewere recorded. InMm. soleus and gastrocnemius, the baicalein effect (increasing number of capillaries per fibre) was proportional to the dose applied.The fibre diameters and area under baicalein treatment were significantly greater compared to OVX and NON-OVX groups. In M. longissimus, we observed a shift to type IIa fibres. Serum creatine kinase levels were significantly lower in highest baicalein concentration group.We conclude that baicalein can stimulate angiogenesis, though not fibre type-specific, in skeletal muscle and reduce the estrogen-related loss of fibre diameter and area in the skeletal muscle in rats.Therefore, a protective effect of baicalein on muscle cells can be assumed."],["dc.identifier.doi","10.1155/2016/3703216"],["dc.identifier.pmid","28050282"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14099"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58815"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66246"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2090-0732"],["dc.relation.issn","2090-0724"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Effect of the Lipoxygenase Inhibitor Baicalein on Muscles in Ovariectomized Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1281"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Archives of Orthopaedic and Trauma Surgery"],["dc.bibliographiccitation.lastpage","1287"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","Menger, Bjoern"],["dc.contributor.author","Kannenberg, Andreas"],["dc.contributor.author","Petersen, Wolf"],["dc.contributor.author","Zantop, Thore"],["dc.contributor.author","Rembitzki, Ingo"],["dc.contributor.author","Stinus, Hartmut"],["dc.date.accessioned","2018-11-07T10:09:37Z"],["dc.date.available","2018-11-07T10:09:37Z"],["dc.date.issued","2016"],["dc.description.abstract","Unloader braces are non-surgical treatment options for patients with unicompartmental knee osteoarthritis (OA). However, many patients do not adhere to brace treatment because of complications related to discomfort and poor fit. An alternative to knee bracing is an ankle-foot orthosis (AFO) with a lever arm that presses the lower leg into valgus or varus. The aim of this study is to evaluate the clinical benefits of this AFO for patients with unicompartmental knee OA. Twenty-three patients with knee OA were enrolled in this observational study. The primary clinical outcome measure was the Western Ontario and McMasters Universities Arthritis Index (WOMAC) total score. Secondary outcome measures included WOMAC subscores, visual analogue pain scale, activity restriction and complication rate. Clinical scores were collected at start and 3, 6, 9, and 12 months after enrollment. Statistical evaluation was performed using the Student's t test. Of the patients enrolled, 83 % suffered from medial compartment OA. Most patients had Grade II OA according to the Kellgren and Lawrence classification. WOMAC total score, both subscores and visual analogue pain scale were significantly improved over time. Patients also noted a reduction in restrictions to activities of daily living and sport-related activities while using the AFO. No patients discontinued orthosis use because of adverse effects. Two types of complications were noted: discomfort or light pressure sores around the ankle (7 patients), and wear and tear of the shoe in which the AFO was worn (14 patients). This observational study suggests that this AFO is effective at significantly reducing pain and stiffness as well as improving the physical function of patients with mild to moderate unicompartmental osteoarthritis of the knee."],["dc.description.sponsorship","Otto Bock Health Care"],["dc.identifier.doi","10.1007/s00402-016-2500-2"],["dc.identifier.isi","000382009600013"],["dc.identifier.pmid","27393498"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39685"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1434-3916"],["dc.relation.issn","0936-8051"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Effects of a novel foot-ankle orthosis in the non-operative treatment of unicompartmental knee osteoarthritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","134"],["dc.bibliographiccitation.journal","Bone"],["dc.bibliographiccitation.lastpage","144"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Saul, D."],["dc.contributor.author","Gleitz, S."],["dc.contributor.author","Nguyen, H. H."],["dc.contributor.author","Kosinsky, R. L."],["dc.contributor.author","Sehmisch, S."],["dc.contributor.author","Hoffmann, D. B."],["dc.contributor.author","Wassmann, M."],["dc.contributor.author","Menger, B."],["dc.contributor.author","Komrakova, M."],["dc.date.accessioned","2018-11-07T10:21:53Z"],["dc.date.accessioned","2020-06-15T07:16:22Z"],["dc.date.available","2018-11-07T10:21:53Z"],["dc.date.available","2020-06-15T07:16:22Z"],["dc.date.issued","2017"],["dc.description.abstract","Osteoporosis is one of the most common diseases worldwide. In osteoporosis, vertebral fractures represent a major burden. Lipoxygenase (LOX) inhibitors such as baicalein and zileuton may represent a promising therapeutic option owing to their antioxidative effects and suppression of various inflammatory processes in muscle and bone. The effect of these LOX inhibitors on the spine was studied in osteopenic rats. Female Sprague-Dawley rats were divided two times into five groups: four groups each were ovariectomized (OVX) and one control group was non-ovariectomized (NON-OVX). Eight weeks after ovariectomy, three concentrations of baicalein (1 mg/kg body weight [BW], 10 mg/kg BW, and 100 mg/kg BW) were administered subcutaneously daily in three OVX groups for 4 weeks. Similarly, zileuton was administered in three concentrations via food for 5 weeks. In vivo computed tomography (pQCT) of the spine was performed before the treatments and at the end of the experiment. Lumbar vertebrae were subjected to a compression test, micro-CT, and ashing analyses. After baicalein treatment, cortical bone mineral density (BMD) was improved; trabecular connectivity and trabecular BMD were diminished at high dose. After zileuton treatment the total BMD, anorganic weight, trabecular nodes, and trabecular area were improved. The in vivo stress-strain index was increased and alkaline phosphatase activity in serum was enhanced after both treatments. A dose-dependent effect was not clearly observed after both treatments. The treatments using baicalein for 4 and zileuton for 5 weeks were not sufficient to change the biomechanical properties and bone volume fraction (BV/TV). Overall, baicalein improved the cortical bone parameters whereas zileuton had a favorable effect on the trabecular structure. Moreover, both treatments increased the bone formation rate. Longer trials, a combination of both LOX inhibitors, and their effect at the cellular and molecular levels should be investigated in further studies. (C) 2017 Elsevier Inc. All rights reserved."],["dc.description.sponsorship","Elsbeth Bonhoff Stiftung [N114]"],["dc.identifier.doi","10.1016/j.bone.2017.04.011"],["dc.identifier.isi","000404319300017"],["dc.identifier.pmid","28455215"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42182"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","8756-3282"],["dc.relation.issn","1873-2763"],["dc.title","Effect of the lipoxygenase-inhibitors baicalein and zileuton on the vertebra in ovariectomized rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]